The FDA has issued a complete response letter to Capricor Therapeutics, requesting additional efficacy data for Deramiocel, its off-the-shelf cell therapy targeting cardiac complications of Duchenne muscular dystrophy. Capricor expressed surprise at the decision and plans to focus on forthcoming Phase III trial results to address FDA concerns. This move diverges from recent regulatory flexibility trends seen in Duchenne drug approvals.